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Prostaglandin D2 receptor D-type prostanoid receptor 2 mediates eosinophil
trafficking into the esophagus
S. Zhang, X. Wu, S. Yu
Division of Gastroenterology, Department of Medicine, University of Michigan Medical School, Ann Arbor,
Michigan, USA
SUMMARY. Eosinophilic esophagitis is characterized by eosinophil-predominant inflammation in the esophagus.
How eosinophils migrate and infiltrate into the esophagus, however, is less clear. Our previous study demonstrated
that mast cell activation led to eosinophil infiltration in the esophagus. Prostaglandin D2 (PGD2) is an important
mediator released from activated mast cells. The present study aims to determine whether PGD2 induces eosinophil
infiltration into the esophagus via a D-type prostanoid receptor 2 (DP2) receptor-dependent mechanism. Using an
in vivo guinea pig model, PGD2, D-type prostanoid receptor 1 (DP1) agonist, or DP2 agonist were injected into the
esophagus. Esophageal tissues were removed 2 hours after injections and proceeded to either hematoxylin–eosin
(HE) staining or immunofluorescent staining of eosinophil major basic protein (MBP) to compare each treatment-
induced eosinophil infiltration in the esophagus. In a separate study, ovalbumin (OVA)-sensitized guinea pigs
were pretreated with either DP2 or DP1 antagonists, followed by inhalation of OVA to induce mast cell activation.
Esophageal tissues were then processed for immunofluorescent staining of MBP. PGD2 injection in the
esophagus led to an increase of eosinophil infiltration in esophageal epithelium at the injection site as revealed by
HE staining. Increased infiltration of eosinophils was further confirmed by the increased presence of MBP-labeled
immunopositive (MBP-LI) cells in esophageal epithelium. Injection with DP2 agonist 15(R)-PGD2, but not DP1
agonist BW 245C, mimicked the PGD2-induced response. In OVA-sensitized animals, antigen inhalation increased
MBP-LI cells in esophageal epithelium. Pretreatment with DP2 antagonist BAY-u3405, but not DP1 antagonist
BW 868C, inhibited the antigen inhalation-induced increase of MBP-LI cells in esophageal epithelium. These data
support the hypothesis that PGD2 induces eosinophil trafficking into the esophageal epithelium via a DP2-
mediated pathway, suggesting a role of DP2 antagonist in the prevention of eosinophilic esophagitis.
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INTRODUCTION
Eosinophilic esophagitis (EoE) has emerged in the
last two decades as a significant esophageal disorder
affecting all age groups.1 In esophageal biopsy, 15
eosinophils per high-power field under microscope
are considered a minimum threshold for the diagno-
sis of EoE.1,2 Eosinophils are derived from CD
34 + hematopoietic progenitor cells in the bone
marrow and are found mainly in circulation rather
than in peripheral tissues. Normal human esophageal
tissue has only minimal eosinophils,3 but their
number increased in the inflamed esophagus.4 Even
though increased infiltration and degranulation of
eosinophils are the predominant features of EoE,
other inflammatory cells such as mast cells and
T-helper cells may also play important roles in the
development of EoE. Currently, the mechanisms
of eosinophil migration from the circulation with
infiltration into the esophagus are still less clear.
Previous studies demonstrated that certain Th2
cytokines and chemokines such as interleukin (IL)-5,
IL−13, and eotaxin play important roles in this infil-
tration process.1 A recent clinical trial revealed that
anti-IL-5 antibody therapy significantly reduces, but
does not normalize, esophageal eosinophil infiltra-
tion in patients with EoE, and clinical symptom
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improvement is not as promising5 as diet elimina-
tion.6 This suggests that factors other than the Th2
cytokine IL-5 may also contribute to this infiltration
process.
Recently, several studies have demonstrated that
there are increased numbers of mast cells in the
esophagus in patients with EoE.7–10 An important
human subject study revealed that esophageal mast
cell degranulation and mastocytosis significantly
increased in patients with EoE, and such increase was
correlated with the expression of transcripts for mast
cell proteases carboxypeptidase A3 and tryptase.10
This suggests that mast cells may play an important
role in the development of EoE. Activated mast cells
not only release preformed mediators such as hista-
mine and tryptase, but also produce de novo synthe-
sized lipid mediators including prostaglandin D2
(PGD2) and leukotrienes D4, etc. Both histamine and
PGD2 are identified to play important roles as
chemoattractants to induce eosinophil infiltration
into the airway of patients with asthma. Our previous
study demonstrated that mast cell preformed media-
tor histamine plays an important role in mast cell
activation-induced eosinophil infiltration in the
esophagus.11 In the present study, we aimed to deter-
mine the role of PGD2 in mast cell activation-
induced infiltration of eosinophils in the esophagus.
The biological effects of PGD2 are usually medi-
ated by its two G-protein-coupled receptors: d-type
prostanoid receptor 1 (DP1) and d-type prostanoid
receptor 2 (DP2) (also known as CRTH2: chemo-
attractant homologous receptor expressed on Th2
cells). We hypothesized that PGD2 could induce
eosinophil infiltration in the esophagus via a DP2-
dependent mechanism. Our present data demon-
strated that PGD2 injection into the esophagus leads
to an increased infiltration of eosinophils in the
esophagus. DP2 agonist was able to mimic this effect.
Pretreatment with DP2 antagonist prevented mast
cell activation-induced infiltration of eosinophils in
the esophagus. This result provided the first evidence
that mast cell mediator PGD2 plays an important
role in eosinophil trafficking into the esophagus.
MATERIALS AND METHODS
Male Hartley guinea pigs (Hilltop Laboratory
Animals, Inc., Scottsdale, PA, USA) weighing 100–
300 g were used. All experiments were approved by
the University of Michigan Committee on Use and
Care of Animals.
PGD2 and agonists injections in the esophagus
Naive guinea pigs were anesthetized by intra-
peritoneal (IP) injection of urethane (1.1 mg/kg). The
cervical esophagus was surgically exposed; PGD2
(n = 4), DP2 agonist 15(R)-PGD2 (n = 3), or DP1
agonist BW 245C (n = 3) were injected (each with
20 μL at 100 nM) into the wall of the esophagus
(70 mm from incisors), respectively. Control animals
received phosphate-buffered saline (PBS) injections.
Two hours after injections, animals were killed by
CO2 inhalation and exsanguination. The esophagi
were removed, processed, and sectioned for HE stain-
ing or immunofluorescent staining of major basic
protein (MBP).
Active immune sensitization and allergen challenge
In a separate study, guinea pigs were actively sen-
sitized and challenged by allergen as previously
described.11 Briefly, guinea pigs were given three IP
injections of ovalbumin (OVA, 10 mg/kg) every 48
hours. Three weeks after the last injection, guinea
pigs were exposed to aerosolized antigen (0.1% OVA)
in a plastic chamber for 2–10 minutes depending on
the development of dyspnea. The OVA was dissolved
in 0.9% saline and delivered using a nebulizer driven
by compressed air. As control, sensitized animals
were exposed for 10 minutes to aerosolized 0.9%
saline by the same technique. The guinea pigs were
closely monitored for signs of any allergic responses
such as gasping or increased respiratory rate. Once
guinea pigs developed such responses, they were
removed and allowed to breathe ambient air.
Animals were euthanized by CO2 inhalation and
exsanguination 2 hours after OVA challenge. Two
additional groups of sensitized animals received
intravenous injection of either BAY-u3405 (DP2
receptor antagonist, at a dose of 5 mg/kg, Cayman
Chemicals, Ann Arbor, MI, USA) or BW A868C
(DP1 antagonist, at a dose of 0.1 mg/kg, Cayman
Chemicals) 30 minutes prior to OVA-challenge. The
doses of antagonists in the present study were selected
according to previous reports.12,13 Animals were sac-
rificed 2 hours after OVA challenge by CO2 inhala-
tion and exsanguination.
Tissue preparation
Esophageal segments were fixed in 10% formalin and
embedded in paraffin. Sections of 5 μm were cut,
mounted on Superfrost Plus glass slides (Fisher Sci-
entific, Pittsburgh, PA, USA), and stained with
hematoxylin–eosin (HE). For immunofluorescent
staining, the esophagus was first fixed in 4% formal-
dehyde in PBS overnight at 4°C. The tissues were
rinsed in PBS and cryoprotected with 18% sucrose in
PBS for 18–24 hours. The tissues were then covered
with optimal cutting temperature mounting medium
and frozen on dry ice. The segments of the esophagus
were cut in serial cross-sections of 12 μm thickness
using a cryostat, collected on silane-coated slides, and
air-dried for 30 minutes.
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Immunofluorescent staining of MBP
Immunofluorescent staining was performed accord-
ing to the method described earlier.11,14 Briefly,
sections were incubated with blocking solution con-
taining 1% bovine serum albumin (BSA), 10% normal
goat serum, and 0.1%Tween 20 in PBS for 60minutes.
The tissues were incubated 12–24 hours at 4°C with
primary antibodies in PBS containing 0.1% Triton
X-100 and 1% BSA (PBS-TX-BSA). The primary
antibody was monoclonal mouse anti-MBP (1:200;
Chemicon (EMD Millipore), Billerica, MA, USA).
Slides were then washed in PBS-TX-BSA and incu-
bated with goat anti-mouse antibody labeled with
Alexa Fluor 594 (diluted 1:200, Invitrogen, Grand
Island, NY, USA) in PBS-TX-BSA for 2 hours at
room temperature. The sectionswere rinsedwith PBS,
then with saline buffered with phosphate to pH 8.6,
and coverslipped. The slides were analyzed and
counted using a conventional epifluorescence micro-
scope (Olympus BX60, Olympus Imaging America,
Center Valley, PA, USA) with the filters set to allow
separate visualization of Alexa 594 (rhodamine;
Invitrogen) in a computer-aided digital imaging
system. The stained slides were briefly checked under
an epifluorescence microscope, and three well-stained
cross-sections from each esophageal specimen were
randomly selected for counting and averaging. Posi-
tive stainings were identified as having pixel intensity
above background fluorescence.
Data analysis
In HE staining, eosinophils in the cross-sections of
the esophagus were counted and averaged from three
high-power fields (400×) under light microscope. In
immunostaining, the total numbers of MBP-positive
eosinophils were counted and averaged from three
cross-sections of each esophageal specimen. Values
were expressed as mean ± standard error of the mean.
Differences between the values were determined by
Student’s t-test, and P < 0.05 was considered statisti-
cally significant.
RESULTS
Effect of PGD2 on eosinophil trafficking into
the esophagus
In naïve guinea pigs, PGD2 injection into the esopha-
gus increased eosinophil infiltration in esophageal
epithelium, as revealed by HE staining at injection
site (PGD2 vs. PBS: 25 ± 1.7/mm2 vs. 7.7 ± 1.0/mm2,
P < 0.01, n = 3). This increased infiltration was a
localized phenomenon, as no increased infiltration of
eosinophils was observed in the tissues either 3 mm
above (5.3 ± 1.3/ mm2) or below (5.3 ± 0.3/mm2) the
injection site (P < 0.05, n = 3) (Fig. 1). The affected
tissue demonstrated elongation of subepithelial papil-
lae (% of mucosal thickness: 58 ± 4%, vs. control at
44 ± 13%, P < 0.05, n = 3). There was no obvious
infiltration of other inflammatory cells (such as
neutrophils) at the injection site. The infiltration of
eosinophils in the esophagus was further confirmed
by the staining of MBP-labeled immunoreac-
tive (MBP-LI) cells in the esophageal epithelium
(17 ± 2.7/cross-section, vs. control of 6.3 ± 1.3/cross-
section, P < 0.05, n = 3).
Effects of DP1 and DP2 agonists on eosinophil
trafficking into the esophagus
To determine the exact roles of DP1 and DP2 on
PGD2-induced eosinophil trafficking into the eso-
phagus, either DP1 or DP2 agonist was injected into
the wall of the esophagus of naïve animals in the same
way as PGD2 injection. Two hours after injections,
esophageal tissueswere processed for immunostaining
of eosinophil MBP. Injection with the DP2 agonist
15(R)-PGD2 significantly increased MBP-positive
eosinophils in esophageal epithelium (DP2 agonist vs.
PBS: 25 ± 4.8/cross-section vs. 6.3 ± 1.3/cross-section,
P < 0.05, n = 3) (Fig. 2A,B). In contrast, injection
with the DP1 agonist BW 245C did not significantly
increase MBP-positive eosinophils in esophageal
epithelium (DP1 agonist vs. PBS: 9.6 ± 1.6/cross-
section vs. 6.3 ± 1.3/cross-section, P > 0.05, n = 3)
(Fig. 2A,C). These results that DP2 agonist, but not
DP1 agonist, mimicked PGD2-induced eosinophil
infiltration in the esophagus suggest an important role
ofDP2 receptor in PGD2-induced eosinophil traffick-
ing into the esophagus.
Effect of DP1 and DP2 antagonists on OVA
challenge-induced eosinophil trafficking into
the esophagus
In OVA-sensitized guinea pigs, allergen (OVA)
challenge by inhalation of nebulized OVA (0.1%)
caused an allergic response resulting in gasping and
increased respiratory rate within 1–5 minutes in all
studied animals (n = 3). Animals, if pretreated with
the DP2 antagonist BAY-u3405 (n = 3), did not
develop such allergic responses during the time of
OVA challenge. Similarly, no allergic response was
observed in control animals (inhaled nebulized
0.9% saline in OVA-sensitized guinea pigs, n = 3).
However, animals pretreated with the DP1 antago-
nist BW 868C (n = 3) developed the signs of allergic
responses within 5 minutes.
The total numbers of MBP-positive eosinophils
were counted and compared in cross-sections of the
esophagus from different treatment groups: OVA-
sensitized (OVA-S) animals receiving saline inhala-
tion (as control), OVA-S animals receiving OVA
challenge (OVA-C), OVA-S animals receiving DP1
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antagonist pretreatment followed by OVA-C, and
OVA-S animals receiving DP2 antagonist pretreat-
ment followed by OVA-C. In control animals
(OVA-S, plus 0.9% saline inhalation), the total
number of MBP-positive eosinophils in the esopha-
gus was 6.5 ± 0.5 cells/cross-section (n = 3). The total
number of MBP-positive eosinophils was signifi-
cantly increased to 36.3 ± 0.9 cells/cross-section in
the OVA-C group (n = 3, vs. control, P < 0.01). Pre-
treatment with the DP2 antagonist BAY-u3405,
significantly inhibited OVA challenge-induced eosi-
nophil infiltration in the esophagus (BAY-u3405 +
OVA-C vs. OVA-C: 12.6 ± 1.9 cells/cross-section vs.
36.3 ± 0.9 cells/cross-section, P < 0.01, n = 3) versus
controls. In contrast, pretreatment with DP1 antago-
nist BW A868C did not significantly inhibit eosino-
phil infiltration in the esophagus induced by OVA
challenge (BW 868C + OVA-C vs. OVA-C: 29.0 ±
3.7 cells/cross-section vs. 36.3 ± 0.9 cells/cross-section,
P > 0.05, n = 3) (Fig. 3). These data support our
hypothesis that DP2 mediates PGD2-induced eosino-
phil trafficking into the esophagus.
DISCUSSION
PGD2 is an important inflammatory mediator that
not only participates in mast cell activation-induced
type I hypersensitivity including smooth muscle con-
traction, vascular leak, and vasodilation, but also
displays potent chemotactic effects on eosinophils,
basophils, and Th2 cells. In addition, it may potenti-
ate inflammatory responses induced by other relevant
mediators. Although PGD2 has been shown to be
present in the esophagus, its physiological function
and role in esophageal disorders are still largely
unknown.
PGD2 is mainly synthesized and released from
activated mast cells. The biological effects of PGD2
are usually mediated by its two G-protein-coupled
receptors: DP1 and DP2. The DP1 receptor is more
widely expressed in leukocytes, vasculature, the
central nervous system, retina, lung, and intestine.
The DP2 receptor is predominately expressed in
eosinophils, basophils, and Th2 cells, and mediates
the PGD2-induced chemotactic effect.15,16 The che-
motactic effect of PGD2 on eosinophils was first
reported in mice deficient in PGD2 receptor (DP
receptor). Sensitization and aerosol challenge of
DP-deficient mice with OVA leads to great reduction
of Th2 cytokines and marginal eosinophil infiltration
in the lung, with animals failing to develop airway
hyperreactivity.17 This was followed by the discovery
of a novel PGD2 receptor, CRTH2, which also
shows to play an important role in mediating PGD2-
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Fig. 1 (A) Prostaglandin D2 (PGD2) on eosinophil trafficking into the esophagus. PGD2 injection into the wall of the esophagus
induces a localized increase of eosinophil infiltration in the esophagus. Compared with control with phosphate-buffered saline (PBS)
injection, PGD2 injection significantly increases eosinophil infiltration in the esophagus as counted in hematoxylin–eosin (HE)-stained
esophageal cross-sections (PBS vs. PGD2: 7.2 ± 1.0 vs. 25±1.7/mm2, P < 0.01, n = 3–4). Such increase is not observed either 3 mm above
or below the injection site. (B) Esophageal cross-section under HE staining. (C) High-power field of HE staining, highlighting infiltrated
eosinophils (arrows) from esophageal cross-section.
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two PGD2 receptors DP and CRTH2 are now clas-
sified as DP1 and DP2.20
Recent studies revealed that PGD2 receptors play
important roles in mediating eosinophil migration
and infiltration in the peripheral tissues, such as the
airway13,21 and skin.22,23 Accumulated evidence consis-
tently supports a predominant role of DP2 in PGD2-
induced chemotactic effect on eosinophils.24–28 But it
is still unclear whether mast cell PGD2 also induces
eosinophil trafficking into the esophagus. The present
study provides the first evidence that PGD2 induces
eosinophil trafficking into the esophagus, that this
chemotactic effect is mimicked by DP2 agonist and
that it can be prevented by DP2 antagonist, suggest-
ing an important role for DP2 in this process. This is
in agreement with the aforementioned observations
in the skin and airway that under allergic and inflam-
matory conditions, PGD2 released from mast cells
plays a predominant role in recruiting eosinophils
into the peripheral tissues.
OVA inhalation in OVA-sensitized animals leads
to type I hypersensitivity and specifically induces
mast cell activation. This model has been widely
applied as an asthma model to study allergic response
in the airway. EoE is usually accompanied with an
allergic condition such as food allergy or aeroallergen
sensitization.29 We believe that the data from the
asthma model are of relevance to EoE, especially
when investigating the specific roles of mast cells and








































Fig. 2 Prostaglandin D2 (PGD2), DP1 agonist, and DP2 agonists on eosinophil trafficking into the esophagus. (A) Injection with
PGD2 increases major basic protein (MBP)-positive-labeled eosinophils in the esophagus. This effect is mimicked by DP2 agonist
15(R)-PGD2, but not by DP1 agonist BW 245C. (B) Immunofluorescent staining of eosinophil MBP in esophageal cross-section after
esophageal injection of DP2 agonist 15(R)-PGD2; (C) Immunofluorescent staining of MBP in esophageal cross-section after esophageal
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Fig. 3 Prostaglandin D2 (PGD2) DP1 and DP2 antagonists on
eosinophil infiltration in the esophagus. In ovalbumin (OVA)-
sensitized guinea pigs, OVA challenge significantly increases
MBP-positive-labeled eosinophils in the esophagus (OVA-S
vs. OVA-S + OVA-C: 6.5 ± 0.5 vs. 36.3 ± 0.9/cross-section,
P < 0.01, n = 3). This effect can be prevented by pretreatment
with DP2 antagonist BAY-u3405 (5 mg/kg, iv) (OVA-S +
OVA-C vs. BAY-u3405 + OVA-S + OVA-C: 36.3 ± 0.9 vs.
12.6 ± 1.6/cross-section, P < 0.01, n = 3), but not by DP1
antagonist BW A868C (100 μg/kg, iv) (OVA-S + OVA-C vs.
BW A868C + OVA-S + OVA-C: 36.3 ± 0.9 vs. 29.0 ± 3.7/
cross-section, P > 0.05, n = 3).
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PGD2 on eosinophil trafficking in the tissue. In the
present study, antagonist effect was determined by
using in vivo guinea pig model as we previously
described.11 This model has inherent limitations and
cannot rule out whether other mediators and factors,
such as histamines, Th2 cytokines, and eotaxin, may
also have roles in eosinophil trafficking into the
esophagus. Based on the present observations, two
important considerations need to be clarified. First,
whether the expression of eotaxin increases in the
esophagus after local injections with PGD2 and DP2
agonist. Second, whether the DP2 antagonist BAY-
u3405 dose dependently inhibits eosinophil infiltra-
tion in the esophagus induced by OVA inhalation.
Additionally, further studies using PGD2 receptor
knockout mice with more localized antigen challenge
in the esophagus could help to better understand the
underlying mechanism of PGD2-induced eosinophil
trafficking into the esophagus.
In summary, the present study for the first time
demonstrated that PGD2 induces eosinophil traffick-
ing into the esophagus. This chemotactic effect is
mediated by DP2 receptor, suggesting a potential role
of DP2 antagonist in the prevention of EoE.
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